Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 171

1.

Safety of Intravenous Immunoglobulin (Tegeline®), Administered at Home in Patients with Autoimmune Disease: Results of a French Study.

Hachulla E, Le Masson G, Solé G, Hamidou M, Desnuelle C, Azulay JP, Besson G, Swiader L, Abad S, Antoine JC, Bouhour F, Créange A, Grenouillet M, Magy L, Marcel S, Paquet JM, Rouhart F, Ziegler F, Mathis S, Gauthier-Darnis M, Puget S.

Biomed Res Int. 2018 Mar 15;2018:8147251. doi: 10.1155/2018/8147251. eCollection 2018.

2.

Phenotypic and genotypic studies of ALS cases in ALS-SMA families.

Corcia P, Vourc'h P, Blasco H, Couratier P, Dangoumau A, Bellance R, Desnuelle C, Viader F, Pautot V, Millecamps S, Bakkouche S, Salachas F, Andres CR, Meininger V, Camu W.

Amyotroph Lateral Scler Frontotemporal Degener. 2018 Aug;19(5-6):432-437. doi: 10.1080/21678421.2018.1440406. Epub 2018 Mar 1.

PMID:
29493298
3.

Home versus hospital immunoglobulin treatment for autoimmune neuropathies: A cost minimization analysis.

Le Masson G, Solé G, Desnuelle C, Delmont E, Gauthier-Darnis M, Puget S, Durand-Zaleski I.

Brain Behav. 2018 Jan 26;8(2):e00923. doi: 10.1002/brb3.923. eCollection 2018 Feb.

4.

Brain computer interface with the P300 speller: Usability for disabled people with amyotrophic lateral sclerosis.

Guy V, Soriani MH, Bruno M, Papadopoulo T, Desnuelle C, Clerc M.

Ann Phys Rehabil Med. 2018 Jan;61(1):5-11. doi: 10.1016/j.rehab.2017.09.004. Epub 2017 Oct 10.

5.

July 2017 ENCALS statement on edaravone.

Al-Chalabi A, Andersen PM, Chandran S, Chio A, Corcia P, Couratier P, Danielsson O, de Carvalho M, Desnuelle C, Grehl T, Grosskreutz J, Holmøy T, Ingre C, Karlsborg M, Kleveland G, Koch JC, Koritnik B, KuzmaKozakiewicz M, Laaksovirta H, Ludolph A, McDermott C, Meyer T, Mitre Ropero B, Mora Pardina J, Nygren I, Petri S, Povedano Panades M, Salachas F, Shaw P, Silani V, Staaf G, Svenstrup K, Talbot K, Tysnes OB, Van Damme P, van der Kooi A, Weber M, Weydt P, Wolf J, Hardiman O, van den Berg LH.

Amyotroph Lateral Scler Frontotemporal Degener. 2017 Nov;18(7-8):471-474. doi: 10.1080/21678421.2017.1369125. Epub 2017 Oct 4. Review. No abstract available.

6.

A study on the safety and efficacy of reveglucosidase alfa in patients with late-onset Pompe disease.

Byrne BJ, Geberhiwot T, Barshop BA, Barohn R, Hughes D, Bratkovic D, Desnuelle C, Laforet P, Mengel E, Roberts M, Haroldsen P, Reilley K, Jayaram K, Yang K, Walsh L; POM-001/002 Investigators.

Orphanet J Rare Dis. 2017 Aug 24;12(1):144. doi: 10.1186/s13023-017-0693-2.

7.

First clinical and genetic description of a family diagnosed with late-onset Pompe disease from Costa Rica.

Torrealba-Acosta G, Rodríguez-Roblero MC, Bogantes-Ledezma S, Carazo-Céspedes K, Desnuelle C.

Neuromuscul Disord. 2017 Oct;27(10):951-955. doi: 10.1016/j.nmd.2017.06.010. Epub 2017 Jun 20.

PMID:
28694071
8.

Care management in amyotrophic lateral sclerosis.

Soriani MH, Desnuelle C.

Rev Neurol (Paris). 2017 May;173(5):288-299. doi: 10.1016/j.neurol.2017.03.031. Epub 2017 Apr 29. Review.

PMID:
28461024
9.

Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled, phase 2 trial.

Meininger V, Genge A, van den Berg LH, Robberecht W, Ludolph A, Chio A, Kim SH, Leigh PN, Kiernan MC, Shefner JM, Desnuelle C, Morrison KE, Petri S, Boswell D, Temple J, Mohindra R, Davies M, Bullman J, Rees P, Lavrov A; NOG112264 Study Group.

Lancet Neurol. 2017 Mar;16(3):208-216. doi: 10.1016/S1474-4422(16)30399-4. Epub 2017 Jan 28.

10.

Short-TERM Neuromuscular Electrical Stimulation Training of the Tibialis Anterior Did Not Improve Strength and Motor Function in Facioscapulohumeral Muscular Dystrophy Patients.

Doix AM, Roeleveld K, Garcia J, Lahaut P, Tanant V, Fournier-Mehouas M, Desnuelle C, Colson SS, Sacconi S.

Am J Phys Med Rehabil. 2017 Apr;96(4):e56-e63. doi: 10.1097/PHM.0000000000000705.

PMID:
28129235
11.

Long term follow-up of cerebrovascular abnormalities in late onset Pompe disease (LOPD).

Garibaldi M, Sacconi S, Antonini G, Desnuelle C.

J Neurol. 2017 Mar;264(3):589-590. doi: 10.1007/s00415-017-8396-0. Epub 2017 Jan 24. No abstract available.

PMID:
28120044
12.

Bent spine syndrome as the initial symptom of late-onset Pompe disease.

Taisne N, Desnuelle C, Juntas Morales R, Ferrer Monasterio X, Sacconi S, Duval F, Sole G, Flipo RM, Lacour A, Vermersch P, Cardon T.

Muscle Nerve. 2017 Jul;56(1):167-170. doi: 10.1002/mus.25478. Epub 2016 Nov 30.

PMID:
27862019
13.

Early diaphragm pacing in patients with amyotrophic lateral sclerosis (RespiStimALS): a randomised controlled triple-blind trial.

Gonzalez-Bermejo J, Morélot-Panzini C, Tanguy ML, Meininger V, Pradat PF, Lenglet T, Bruneteau G, Forestier NL, Couratier P, Guy N, Desnuelle C, Prigent H, Perrin C, Attali V, Fargeot C, Nierat MC, Royer C, Ménégaux F, Salachas F, Similowski T.

Lancet Neurol. 2016 Nov;15(12):1217-1227. doi: 10.1016/S1474-4422(16)30233-2. Epub 2016 Oct 11. Erratum in: Lancet Neurol. 2016 Dec;15(13):1301.

PMID:
27751553
14.

Therapeutic target of memory B cells depletion helps to tailor administration frequency of rituximab in myasthenia gravis.

Lebrun C, Bourg V, Bresch S, Cohen M, Rosenthal-Allieri MA, Desnuelle C, Ticchioni M.

J Neuroimmunol. 2016 Sep 15;298:79-81. doi: 10.1016/j.jneuroim.2016.07.009. Epub 2016 Jul 11.

PMID:
27609279
15.

[Expert centers and network in the care organization of ALS patients].

Desnuelle C.

Rev Prat. 2016 May;66(5):569. French. No abstract available.

PMID:
30512585
16.

Unusual association of amyotrophic lateral sclerosis and myasthenia gravis: A dysregulation of the adaptive immune system?

Del Mar Amador M, Vandenberghe N, Berhoune N, Camdessanché JP, Gronier S, Delmont E, Desnuelle C, Cintas P, Pittion S, Louis S, Demeret S, Lenglet T, Meininger V, Salachas F, Pradat PF, Bruneteau G.

Neuromuscul Disord. 2016 Jun;26(6):342-6. doi: 10.1016/j.nmd.2016.03.004. Epub 2016 Mar 29.

PMID:
27102004
17.

Gender as a Modifying Factor Influencing Myotonic Dystrophy Type 1 Phenotype Severity and Mortality: A Nationwide Multiple Databases Cross-Sectional Observational Study.

Dogan C, De Antonio M, Hamroun D, Varet H, Fabbro M, Rougier F, Amarof K, Arne Bes MC, Bedat-Millet AL, Behin A, Bellance R, Bouhour F, Boutte C, Boyer F, Campana-Salort E, Chapon F, Cintas P, Desnuelle C, Deschamps R, Drouin-Garraud V, Ferrer X, Gervais-Bernard H, Ghorab K, Laforet P, Magot A, Magy L, Menard D, Minot MC, Nadaj-Pakleza A, Pellieux S, Pereon Y, Preudhomme M, Pouget J, Sacconi S, Sole G, Stojkovich T, Tiffreau V, Urtizberea A, Vial C, Zagnoli F, Caranhac G, Bourlier C, Riviere G, Geille A, Gherardi RK, Eymard B, Puymirat J, Katsahian S, Bassez G.

PLoS One. 2016 Feb 5;11(2):e0148264. doi: 10.1371/journal.pone.0148264. eCollection 2016.

18.

Identifying a therapeutic window in acute and subacute inflammatory sensory neuronopathies.

Antoine JC, Robert-Varvat F, Maisonobe T, Créange A, Franques J, Mathis S, Delmont E, Kuntzer T, Lefaucheur JP, Pouget J, Viala K, Desnuelle C, Echaniz-Laguna A, Rotolo F, Camdessanché JP; French Neuromuscular Network FILNEMUS.

J Neurol Sci. 2016 Feb 15;361:187-91. doi: 10.1016/j.jns.2015.12.044. Epub 2015 Dec 29.

PMID:
26810539
19.

Modeling Andersen's Syndrome in Human Induced Pluripotent Stem Cells.

Pini J, Rouleau M, Desnuelle C, Sacconi S, Bendahhou S.

Stem Cells Dev. 2016 Jan 15;25(2):151-9. doi: 10.1089/scd.2015.0258. Epub 2015 Dec 30.

PMID:
26573604
20.

The European LEMS Registry: Baseline Demographics and Treatment Approaches.

Mantegazza R, Meisel A, Sieb JP, Le Masson G, Desnuelle C, Essing M.

Neurol Ther. 2015 Dec;4(2):105-24. doi: 10.1007/s40120-015-0034-0. Epub 2015 Nov 2.

Supplemental Content

Loading ...
Support Center